Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.35K Hold
20
﹤0.01% 512
2026
Q1
$1.26K Buy
+20
New +$1.39K ﹤0.01% 469
2025
Q4
Sell
-8,636
Closed -$581K 438
2025
Q3
$581K Sell
8,636
-43,425
-83% -$3.44M 0.01% 256
2025
Q2
$4.54M Buy
52,061
+7,601
+17% +$596K 0.11% 138
2025
Q1
$3.04M Sell
44,460
-5,756
-11% -$470K 0.08% 157
2024
Q4
$3.92M Buy
50,216
+26,884
+115% +$1.99M 0.1% 135
2024
Q3
$1.56M Buy
23,332
+18,356
+369% +$1.51M 0.04% 189
2024
Q2
$564K Sell
4,976
-1,348
-21% -$170K 0.02% 261
2024
Q1
$877K Buy
+6,324
New +$795K 0.03% 232

Other funds holding DXCM

Allianz's DXCM Position: Q2 2026 in Review

Allianz held its DexCom (DXCM) position steady in Q2 2026 at 20 shares worth $1.35K. The position accounts for ﹤0.01% of the portfolio, ranked #512.

Allianz first reported a position in DXCM in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.54M in Q2 2025. 971 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Allianz held 20 shares of DexCom worth $1.35K as of Q2 2026.
  • Allianz left its DexCom share count unchanged in Q2 2026.
  • DexCom made up ﹤0.01% of Allianz's portfolio in Q2 2026, its #512 holding.
  • Allianz first reported a position in DexCom in Q1 2024 and has held it in 9 quarters since.
  • Allianz's DexCom position peaked at $4.54M in Q2 2025.
  • 971 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Allianz's 13F filing for Q2 2026, filed 10 Aug 2026.